{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-001000","form_type":"8-K","ticker":"DNA","cik":"0001830214","company_name":"Ginkgo Bioworks Holdings, Inc.","filed_at":"2024-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.809514+00:00","generated_at":"2026-06-07T01:02:13.723361+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ginkgo Bioworks expects to meet 2023 revenue guidance of $250-260M; cash nearly $950M","bullets":["Preliminary cell engineering revenue $145-150M, biosecurity up to $110M, total revenue $250-260M.","New Cell Programs added expected within 80-85 range, meeting prior guidance.","Biopharma partnerships with Pfizer, Novo Nordisk, Merck, Boehringer Ingelheim; aggregate potential over $1.2B milestones.","Ended 2023 with nearly $950M cash and cash equivalents; strong balance sheet.","Full year 2023 financial results to be reported in February 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-001000","json":"https://secwatch.observer/filing/0001628280-24-001000.json","markdown":"https://secwatch.observer/filing/0001628280-24-001000.md","text":"https://secwatch.observer/filing/0001628280-24-001000.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1830214/000162828024001000/0001628280-24-001000-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1830214/000162828024001000/dna-20240110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:02:13.723361+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"efbc75440a39af84442dc8383549e5eba607df8d","claim":"Ginkgo Bioworks Holdings, Inc. updated its for the year ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"Ginkgo continues to expect Total revenue of $250 – $260 million in 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1830214/000162828024001000/0001628280-24-001000-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the year ended December 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"efbc75440a39af84442dc8383549e5eba607df8d","claim":"Ginkgo Bioworks Holdings, Inc. updated its for the year ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"Preliminary unaudited Cell Engineering revenue is expected to be within the previously disclosed guidance range of $145 – $150 million in 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1830214/000162828024001000/0001628280-24-001000-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the year ended December 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"efbc75440a39af84442dc8383549e5eba607df8d","claim":"Ginkgo Bioworks Holdings, Inc. updated its for the year ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"Preliminary unaudited Biosecurity revenue is expected to be in line with the previously disclosed guidance of up to $110 million in 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1830214/000162828024001000/0001628280-24-001000-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the year ended December 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"efbc75440a39af84442dc8383549e5eba607df8d","claim":"Ginkgo Bioworks Holdings, Inc. updated its for the year ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"New Cell Programs are expected to be within the previously disclosed guidance range of 80-85 new Cell Programs added to the platform in 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1830214/000162828024001000/0001628280-24-001000-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the year ended December 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}